Volker Kunzmann
YOU?
Author Swipe
View article: Impact of Baseline β-Catenin Comutations on Prognosis in EGFR-Mutant Lung Cancer
Impact of Baseline β-Catenin Comutations on Prognosis in EGFR-Mutant Lung Cancer Open
PURPOSE Epidermal growth factor receptor (EGFR) mutations are a main actionable driver in non–small cell lung cancer (NSCLC). However, the clinical significance of catenin beta-1 (CTNNB1) comutations remains unclear. This study evaluated o…
View article: Efficacy of CDK4/6 Inhibition in colorectal cancer and the role of p16 expression in predicting drug resistance
Efficacy of CDK4/6 Inhibition in colorectal cancer and the role of p16 expression in predicting drug resistance Open
Introduction Colorectal cancer (CRC) is a leading cause of cancer-related mortality worldwide. The use of sequential polychemotherapies has improved the survival of patients with advanced metastatic disease. However, the survival rates ach…
View article: Precision oncology – Guideline of the Austrian, German and Swiss Societies for hematology and medical oncology
Precision oncology – Guideline of the Austrian, German and Swiss Societies for hematology and medical oncology Open
Precision oncology is a multi-step process including patient selection, tumor profiling, molecular tumor board discussion and personalized cancer management. So far, it remains largely unstandardized. The implementation of precision oncolo…
View article: Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition
Long-term disease control in dedifferentiated liposarcoma: a case report on trabectedin priming followed by PD-1 inhibition Open
Background Dedifferentiated liposarcoma (DDLPS) is a rare mesenchymal cancer originating from the adipose tissue, with poor survival rates for most patients, highlighting the critical need for novel treatment options. Case description This…
View article: Minimally invasive determination of pancreatic ductal adenocarcinoma ( <scp>PDAC</scp> ) subtype by means of circulating cell‐free <scp>RNA</scp>
Minimally invasive determination of pancreatic ductal adenocarcinoma ( <span>PDAC</span> ) subtype by means of circulating cell‐free <span>RNA</span> Open
Pancreatic ductal adenocarcinoma (PDAC) comprises two clinically relevant molecular subtypes that are currently determined using tissue biopsies, which are spatially biased and highly invasive. We used whole transcriptome sequencing of 10 …
View article: Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116)
Sequential therapy of refractory metastatic pancreatic cancer with 5-FU/LV/irinotecan (FOLFIRI) vs. 5-FU/LV/oxaliplatin (OFF). The PANTHEON trial (AIO PAK 0116) Open
Purpose In patients with metastatic pancreatic cancer, after failure of gemcitabine/nab-paclitaxel, this trial compares the efficacy of second-line therapy with FOLFIRI vs. OFF (1:1 randomisation) with cross-over to the vice-versa regimen …
View article: The WERA cancer center matrix: Strategic management of patient access to precision oncology in a large and mostly rural area of Germany
The WERA cancer center matrix: Strategic management of patient access to precision oncology in a large and mostly rural area of Germany Open
The WERA matrix provided a transparent portfolio of postal code areas, which helped assessing the geographical impact of our PO program. We believe that its intuitive principle can easily be transferred to other cancer centers.
View article: The WERA Cancer Center Matrix: Strategic Management of Patient Access to Precision Oncology in a Large and Mostly Rural Area of Germany
The WERA Cancer Center Matrix: Strategic Management of Patient Access to Precision Oncology in a Large and Mostly Rural Area of Germany Open
Purpose Offering equal Patient Access to Precision Oncology (PO) is a major challenge of clinical oncologists and cancer center representatives. Here, we provide an easily transferable model adopted from strategic management science to ass…
View article: European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission
European Stop Tyrosine Kinase Inhibitor Trial (EURO-SKI) in Chronic Myeloid Leukemia: Final Analysis and Novel Prognostic Factors for Treatment-Free Remission Open
Clinical trials frequently include multiple end points that mature at different times. The initial report, typically based on the primary end point, may be published when key planned co-primary or secondary analyses are not yet available. …
View article: Minimally invasive determination of PDAC subtype and therapy-induced subtype switch by means of circulating cell-free RNA
Minimally invasive determination of PDAC subtype and therapy-induced subtype switch by means of circulating cell-free RNA Open
Background Pancreatic ductal adenocarcinoma (PDAC) comprises two clinically relevant subtypes. Currently, determining the tumor subtype relies on tissue biopsies. Unfortunately, these biopsies are spatially biased, highly invasive, difficu…
View article: Gastroesophageal Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023
Gastroesophageal Oncology Highlights from the European Society for Medical Oncology Annual Meeting 2023 Open
The European Society for Medical Oncology (ESMO) annual meeting was hosted in Madrid in October 2023. As Young Medical Oncologists of the German working group for "Internal Oncology" ("AIO: Arbeitsgruppe Internistische Onkologie") we repor…
View article: 715 ICT01 plus low dose SC IL-2 produces a robust anti-tumor immune activation in advanced cancer patients (EVICTION-2 Study)
715 ICT01 plus low dose SC IL-2 produces a robust anti-tumor immune activation in advanced cancer patients (EVICTION-2 Study) Open
Background ICT01 is a first-in-class anti-BTN3A mAb that selectively activates γ9δ2 T cells, leading to remodeling of the tumor microenvironment by activated γ9δ2 T, CD8 T, and NK cells (EVICTION-NCT04243499). However, many cancer patients…
View article: S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL.
S157: NILOTINIB VS. NILOTINIB + PEG-INTERFERON ΑLPHA INDUCTION AND NILOTINIB OR PEG-INTERFERON ΑLPHA MAINTENANCE THERAPY FOR NEWLY DIAGNOSED CHRONIC MYELOID LEUKEMIA PATIENTS. THE TIGER TRIAL. Open
Background: The TIGER-study (NCT01657604) is a multicenter, randomized phase III trial to evaluate efficacy and tolerability of nilotinib (NIL) monotherapy vs NIL+pegylated interferon α2b (IFN) combination therapy with IFN maintenance as f…
View article: The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value for treatment-free remission in chronic myeloid leukemia patients treated with imatinib Open
Membrane transporters are important determinants of drug bioavailability. Their expression and activity affect the intracellular drug concentration in leukemic cells impacting response to therapy. Pharmacogenomics represents genetic marker…
View article: CXCR4-Directed Imaging and Endoradiotherapy in Desmoplastic Small Round Cell Tumors
CXCR4-Directed Imaging and Endoradiotherapy in Desmoplastic Small Round Cell Tumors Open
Desmoplastic small round cell tumor (DSRCT) is a rare, radiosensitive, yet difficult-to-treat sarcoma subtype affecting predominantly male adolescents. Extensive intraperitoneal seeding is common and requires multimodal management. With no…
View article: Integrated Analysis of the RASH Study with the Use of the “Burden of Therapy” (BOTh®TM) Methodology—A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic Cancer
Integrated Analysis of the RASH Study with the Use of the “Burden of Therapy” (BOTh®TM) Methodology—A Novel Tool for Assessing Adverse Events in Metastatic Pancreatic Cancer Open
This analysis of the RASH trial (NCT01729481) aimed at gaining a better understanding of the “Burden of Therapy” (BOTh®TM) in pancreatic ductal adenocarcinoma (PDAC). In the RASH study, 150 patients with newly diagnosed metastatic PDAC wer…
View article: The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value on treatment-free remission in chronic myeloid leukemia patients treated with imatinib
The SNP rs460089 in the gene promoter of the drug transporter OCTN1 has prognostic value on treatment-free remission in chronic myeloid leukemia patients treated with imatinib Open
Membrane transporters are important determinants of drug bioavailability. Their expression and activity affect the intracellular drug concentration in leukemic cells impacting response to therapy. Pharmacogenomics represents genetic marker…
View article: Division of labor and cooperation between different butyrophilin proteins controls phosphoantigen-mediated activation of human γδ T cells
Division of labor and cooperation between different butyrophilin proteins controls phosphoantigen-mediated activation of human γδ T cells Open
Butyrophilin (BTN)-3A and BTN2A1 molecules control TCR-mediated activation of human Vγ9Vδ2 T-cells triggered by phosphoantigens (PAg) from microbes and tumors, but the molecular rules governing antigen sensing are unknown. Here we establis…
View article: Adjuvant <i>nab</i> -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial
Adjuvant <i>nab</i> -Paclitaxel + Gemcitabine in Resected Pancreatic Ductal Adenocarcinoma: Results From a Randomized, Open-Label, Phase III Trial Open
PURPOSE This randomized, open-label trial compared the efficacy and safety of adjuvant nab-paclitaxel + gemcitabine with those of gemcitabine for resected pancreatic ductal adenocarcinoma (ClinicalTrials.gov identifier: NCT01964430 ). METH…
View article: 720 Enhancing the anti-tumor immunity and therapeutic potential of ICT01, a butyrophilin3A-targeted, γ9δ2 T cell-activating monoclonal antibody, with low dose IL-2 in patients with advanced solid tumors: The EVICTION-2 trial
720 Enhancing the anti-tumor immunity and therapeutic potential of ICT01, a butyrophilin3A-targeted, γ9δ2 T cell-activating monoclonal antibody, with low dose IL-2 in patients with advanced solid tumors: The EVICTION-2 trial Open
International audience
View article: Identification of Disparities in Personalized Cancer Care—A Joint Approach of the German WERA Consortium
Identification of Disparities in Personalized Cancer Care—A Joint Approach of the German WERA Consortium Open
(1) Background: molecular tumor boards (MTBs) are crucial instruments for discussing and allocating targeted therapies to suitable cancer patients based on genetic findings. Currently, limited evidence is available regarding the regional i…